 By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT On May 15th, 2020, AzurRx BioPharma, Inc. NASDAQ:AZRX filed its first quarter 2020 10-Q with the SEC for the three month period ending March 31, 2020. Highlights year to date include the appointment of a new CFO and board member, receipt of 3.5 million in French tax credits, confirmation of manufacturing and distribution 